Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Genor Biopharma Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Holding, Subsidiary

Established: 2007-12-04

Employees: 101

Market Cap: -

Website: http://www.genorbio.com

Clinical Trials

A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Solid Tumor Cancer

Interventions: Drug: GB268

First Posted Date: 2025-04-18

Last Posted Date: 2025-04-30

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 330

Registration Number: NCT06934616

A Study of [14C]GB491 in Male Healthy Subjects

Phase 1

Completed

Conditions: Nonsmall Cell Lung Cancer
Breast Cancer

Interventions: Drug: [14C]GB491

First Posted Date: 2023-05-16

Last Posted Date: 2023-05-16

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 6

Registration Number: NCT05860582

Locations: 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, Beijing, China

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: GB491 combined with Letrozole
Drug: Placebo combined with Letrozole

First Posted Date: 2023-05-09

Last Posted Date: 2023-05-09

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 350

Registration Number: NCT05851014

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
The First Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China

and more 49 locations

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Phase 1

Conditions: Advanced Breast Cancer

Interventions: Drug: GB491+Letrozole

First Posted Date: 2022-04-20

Last Posted Date: 2022-04-20

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 10

Registration Number: NCT05337657

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

Phase 1

Recruiting

Conditions: NSCLC
Other Solid Tumors

Interventions: Biological: GB263T

First Posted Date: 2022-04-18

Last Posted Date: 2022-08-05

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT05332574

Locations: 🇦🇺
Genesis Care, Saint Leonards, New South Wales, Australia
🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺
Cabrini Hospital Malvern, Malvern, Victoria, Australia

and more 1 locations

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: GB491+ Fulvestrant
Drug: Placebo+Fulvestrant

First Posted Date: 2021-09-23

Last Posted Date: 2024-10-10

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 275

Registration Number: NCT05054751

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China

and more 51 locations

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

Phase 1

Recruiting

Conditions: B Cell NHL
CLL

Interventions: Biological: GB261

First Posted Date: 2021-06-11

Last Posted Date: 2023-05-22

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 460

Registration Number: NCT04923048

Locations: 🇦🇺
St Vincent's Hospital/The Kinghorn Cancer Centre, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Cabrini hospital, Melbourne, The State Of Victoria, Australia

and more 3 locations

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: GB221
Drug: Herceptin

First Posted Date: 2021-05-27

Last Posted Date: 2021-05-27

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 87

Registration Number: NCT04905667

Locations: 🇨🇳
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangzhou, China

A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients

Phase 1

Conditions: Rheumatoid Arthritis

Interventions: Biological: GB224 10mg
Biological: GB224 20mg

First Posted Date: 2019-11-27

Last Posted Date: 2019-11-27

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04179513

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

Phase 1

Conditions: Rheumatoid Arthritis

Interventions: Other: Placebo, 10mg
Other: Placebo, 20mg
Biological: GB224 15mg
Biological: GB224 30mg
Biological: GB224 10mg
Other: Placebo, 2mg
Other: Placebo, 5mg
Biological: GB224 2mg
Biological: GB224 5mg
Biological: GB224 20mg
Other: Placebo, 15mg
Other: Placebo, 30mg

First Posted Date: 2019-11-26

Last Posted Date: 2019-11-27

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 58

Registration Number: NCT04178070

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy